This novel enhancer is easily integrated into existing workflows, and it produces 2 to 4X higher titers across a range of serotypes, cellular growth media formulations, and transfection platforms. RevIT™ AAV Enhancer can further drive down upstream manufacturing costs by permitting the use of lower levels of plasmid DNA while maintaining high-quality titers. Continual improvements in both upstream and downstream AAV manufacturing processes will allow the next generation of gene therapies to reach a broader audience.

• Designed to deliver a higher titer for any serotype, reagent, media, or cell line. 2 to 4X increase in AAV titer. >50% reduction in cost per dose. 2X doses produced per bioreactor run.